Pharma Equity Group A/S
Pharma Equity Group A/S is an investment holding company that operates within the financials sector, primarily focused on holding and managing investments in the pharmaceutical industry.
Business. Pharma Equity Group A/S (PEGRP.CO) is an investment holding company headquartered in Denmark and listed on the Nasdaq Copenhagen exchange. The firm operates within the Financials sector, specifically classified under Investment Holding Companies. As segment and geographic breakdowns are not disclosed, the company is described at the industry level as an entity engaged in investment holding activities.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Pharma Equity Group A/S (PEGRP.CO) is an investment holding company headquartered in Denmark and listed on the Nasdaq Copenhagen exchange. The firm operates within the Financials sector, specifically classified under Investment Holding Companies. As segment and geographic breakdowns are not disclosed, the company is described at the industry level as an entity engaged in investment holding activities.
Pharma Equity Group A/S has a capital structure marked by a debt-to-equity ratio of 1.23, indicating a moderate level of leverage. The company's liquidity position is characterized by a current ratio of 2.09, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's cash and equivalents amount to 2,199,000 DKK, which is significantly lower than its long-term debt of 39,205,000 DKK, resulting in a negative net cash position.
The company's profitability is currently negative, with a return on equity of -22.58% and a return on assets of -9.16%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The operating and net income are both negative, with operating income at -6,828,000 DKK and net income at -7,170,000 DKK, further underscoring the company's unprofitable operations.
Pharma Equity Group A/S does not disclose specific segments or geographic regions in its financial reporting, making it difficult to assess revenue concentration or geographic exposure. The company's operations are primarily centered around its investment activities, and there is no indication of significant diversification across business lines or regions.
The company's growth trajectory is currently negative, with declining operating and net income. Analysts have estimated a mean EPS of 0.00 DKK, compared to an actual EPS of -0.02 DKK, and a mean revenue estimate of 25,000,000 DKK, compared to an actual revenue of 0.00 DKK. These figures suggest that the company is not meeting expectations and may face challenges in generating revenue and earnings in the near term.
The company's risk profile is characterized by medium liquidity risk and low dilution risk. The key risk flag is the negative net cash position after subtracting total debt, which could impact the company's ability to meet its financial obligations. The dilution risk is low, indicating that the company is not expected to issue additional shares in the near term.
Recent financial filings and transcripts do not provide additional insights into the company's operations or strategic direction. The company's financial performance remains a concern, with no significant events or disclosures that suggest a turnaround in the near future.
- Pharma Equity Group A/S is an investment holding company with a negative return on equity and return on assets, indicating poor profitability.
- The company's debt-to-equity ratio of 1.23 suggests a moderate level of leverage, but its negative net cash position raises liquidity concerns.
- Analyst estimates indicate that the company is not meeting revenue and earnings expectations, suggesting a challenging growth trajectory.
- The company's risk profile is characterized by medium liquidity risk and low dilution risk, with no significant diversification across business lines or regions.
- Recent financial filings and transcripts do not provide additional insights into the company's operations or strategic direction.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Operating income -kr 4.2M.
- ▍Operating income -kr 4.2M
Operating income -kr 5.2M.
- ▍Operating income -kr 5.2M
Operating income -kr 4.9M.
- ▍Operating income -kr 4.9M
Operating income -kr 6.8M.
- ▍Operating income -kr 6.8M
Operating income +19,3% YoY; Net income +37,5% YoY.
- ▍Operating income +19,3% YoY
- ▍Net income +37,5% YoY
- ▍Free cash flow +37,9% YoY
Operating income −3,2% YoY; Net income −66,8% YoY.
- ▍Operating income −3,2% YoY
- ▍Net income −66,8% YoY
- ▍Free cash flow −66,8% YoY
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- Pharma Equity Group A/S Market data — financials · 2026-05-28
- Pharma Equity Group A/S Market data — analyst estimates · 2026-05-28